Related Experiment Video

Updated: Aug 12, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.9K

Use of Sotrovimab in 14 Children with COVID-19: A Single-center Experience

Sarina Kim Butzer1, Sandra Habbig2, Katrin Mehler1

  • 1From the Division of Pediatric Infectious Disease, Department of Pediatrics, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

The Pediatric Infectious Disease Journal
|February 2, 2023
PubMed

Insights

Sotrovimab, a monoclonal antibody, shows good tolerability in children with COVID-19 and underlying health conditions. This treatment offers a potential option for pediatric patients at high risk of severe coronavirus disease 2019.

Area of Science:

  • Pediatric infectious diseases
  • Immunology
  • Pharmacology

Background:

  • Children with preexisting comorbidities face increased risk of severe coronavirus disease 2019 (COVID-19).
  • Monoclonal antibodies are effective in preventing severe COVID-19 in adults, but pediatric data are limited.
  • Sotrovimab is a promising therapeutic option for viral infections.

Purpose of the Study:

  • To evaluate the tolerability and safety of Sotrovimab in pediatric patients at risk for severe COVID-19.
  • To assess the efficacy of Sotrovimab in a pediatric cohort with underlying health conditions.

Main Methods:

  • Retrospective case series of 14 pediatric patients treated with Sotrovimab.
  • Data collected on patient demographics, comorbidities, and treatment outcomes.
  • Adverse events and infusion-related reactions were closely monitored.

Main Results:

  • Sotrovimab was well-tolerated in all 14 pediatric patients.
  • No infusion-related reactions were observed during or after treatment.
  • The treatment was administered at the University of Cologne Children's Hospital.

Conclusions:

  • Sotrovimab demonstrates favorable tolerability and safety in children with COVID-19 and comorbidities.
  • Further research is warranted to establish the efficacy of Sotrovimab in pediatric populations.
  • Sotrovimab represents a potential therapeutic strategy for managing severe COVID-19 in at-risk children.

More Related Videos

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

2.6K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.5K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
69
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
229
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
412
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
154
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K